Source comparison
MK-677 Mechanism of Action Detailed: Comparison
Receptor Target GHS-R1a (ghrelin receptor) in pituitary and hypothalamus Direct GH receptor agonism in peripheral tissues GHS-R1a plus some non-selective binding MK-677's selectivity for GHS-R1a produces cleaner signaling without the cortisol/prolactin elevati
This comparison does not assign a generated winner or score.
- Receptor Target
- GHS-R1a (ghrelin receptor) in pituitary and hypothalamus
- Direct GH receptor agonism in peripheral tissues
- GHS-R1a plus some non-selective binding
- MK-677's selectivity for GHS-R1a produces cleaner signaling without the cortisol/prolactin elevation GHRP-6 causes
- Pulsatility Pattern
- Preserves natural ultradian rhythm with 1.5–2× amplitude peaks
- Flattens rhythm—creates constant serum GH levels
- Mimics natural pulsatility but requires multiple daily doses
- Preserved pulsatility reduces metabolic side effects and maintains hypothalamic sensitivity
- IGF-1 Elevation
- 40–60% above baseline with once-daily oral dosing
- 100–300% depending on dose, sustained elevation
- 30–50% with 3× daily subcutaneous injection
- MK-677 delivers physiological IGF-1 range without supraphysiological spikes or injection burden
- Axis Suppression
- None—GHRH neurons remain responsive, somatotrophs functional
- Severe—pituitary atrophy, months of recovery post-cessation
- Minimal with proper dosing protocols
- Only MK-677 allows indefinite use without axis shutdown or post-cycle GH deficiency
- Half-Life and Dosing
- 4–6 hour plasma half-life, 18–20 hour IGF-1 elevation window, once-daily oral
- 3–5 hour half-life, requires daily subcutaneous injection
- 20–30 minute half-life, requires 2–3 daily injections
- Oral bioavailability and extended IGF-1 response make MK-677 the only secretagogue supporting compliance in long-duration studies
- Bottom Line
- Best option for sustained GH elevation without axis suppression or injection protocols—ideal for metabolic research, longevity studies, and applications requiring 6+ month continuous use
- Fastest route to supraphysiological GH/IGF-1 but guarantees axis shutdown and requires medical oversight for safe cycling
- Middle ground—preserves some axis function but impractical for long-term use due to injection frequency
- MK-677's unique combination of oral administration, preserved feedback loops, and 24-hour receptor occupancy makes it mechanistically superior for research requiring chronic GH elevation without the drawbacks of exogenous hormone replacement